User talk:Yjjong/sandbox

Lots of good work. Keep it up--RJBazell (talk) 16:58, 25 October 2018 (UTC)[reply]

Archer's Peer Review[edit]

You've added significantly to the article, including many new secions substantiated by many great sources. Overall, I think the biggest issue is one of neutrality; I would avoid using phrases like "unfortunately" or, specifically in the "Controversy" section, directly reflecting negatively on Merck. It would work better to frame it as what critics had to say so that it doesn't come across as bias in the article. The section about indinavir anhydrous seems a little abrupt. You could either add an introduction before it to give it context or make it a separate section. Finally, I would be careful not to make generalizations from class in your article without substantiating your statements with direct sources/citation even if we know them to be true. Great job! Keep it up. Joarfr (talk) 02:12, 29 October 2018 (UTC)[reply]

Andrew's Peer Review[edit]

Your article looks good so far, as it looks like you have found a lot of great sources with pretty good information in them. One suggestion that I would like to give you for the organizational aspect is maybe switching the order of the history and clinical trials sections of your article. I say this simply because I would say that the clinical trials are an offshoot of the overall history to date. I also believe that bias needs to be reassessed a little bit, due to the nature of the topic, and how we have negatively discussed big Pharma in class. Straying away from this is crucial to the success of your article. Overall, really good job! Limur34 (talk) 14:03, 29 October 2018 (UTC)[reply]

Eden's Peer Review[edit]

You've added a ton to this article, and I really appreciate the addition of the history of the drug. There are some minor conventional errors with capitalization but that's an easy fix. Additionally, there does seem to be a bit of a bias, however as long as you ensure neutrality you have a pretty effective article. Nice job!--Alignad123 (talk) 18:18, 30 October 2018 (UTC)[reply]